JLE

Hépato-Gastro & Oncologie Digestive

MENU

Immunotherapy in non-colorectal MSI tumors Volume 30, supplement 4, September 2023

Author
Institut Paoli-Calmettes, Département d’Oncologie Médicale, 232 boulevard de Sainte-Marguerite, 13009 Marseille
* Correspondance : C. de la Fouchardière

Non-colorectal MSI/dMMR (microsatellite instability/deficient MMR system) tumors are mostly represented by gastric and small bowel cancers. Nevertheless, their presence is ubiquitous, even if it is very rare in certain anatomical and histological locations. Their management has been revolutionized by the introduction of immune checkpoint inhibitors (ICI) (in particular anti-PD-1 and PD-L-1) which have shown interesting response rates, both in patients with advanced, metastatic disease, but also in a neoadjuvant setting with a localized tumor. Moreover, even if the treatment standards have not evolved in France concerning access to ICI partly due to the absence of randomized comparative study, the search for MSI/dMMR is recommended for any digestive tumor in localized or metastatic situation. In fact, the inclusion of patients in a clinical trial evaluating immunotherapy will be preferred over conventional chemotherapy treatment.